Robyn Goforth, PhD, Vice President Technology Assessment, also presently serving as Chief Scientific Officer for portfolio company BiologicsMD. At BiologicsMD she oversees pre-clinical drug development programs for the pipeline of products for treatment of alopecia, severe bone disorders, and metastatic breast and prostate cancers.
Her primary areas of technical focus are drug development, pharmaceutical manufacturing, and regulatory strategy. With VIC’s Opportunity Assessment Team, Dr. Goforth leads technical and commercial evaluation of technologies ranging from medical devices to pharmaceuticals as well as scientific research tools and instrumentation.
Dr. Goforth has been the principal investigator on over $3M in Small Business Innovation Research and Department of Defense grants and has served as co-principal investigator on over $10MM in National Institutes of Health and Department of Energy grants. Dr. Goforth earned her Doctorate degree in Chemistry from the University of Arkansas in 2001.